Researchers get funding for malaria vaccine
The EU has awarded a network of European researchers Euro 2.4 million to pursue the development of a malaria vaccine.
The EU has awarded a network of European researchers Euro 2.4 million to pursue the development of a malaria vaccine.
Coordinated by Dutch biotechnology company Crucell, researchers will conduct pre-clinical trials over three years of a paediatric vaccine where a version of the BCG (tuberculosis) vaccine is the vector for a malaria antigen.
The BCG is already given to African children at birth, so the team says that combining the two is sensible. Participants will study animals to investigate the effectiveness and best dose of the vaccine. Crucell cso Jaap Goudsmit, said: 'The grant is important to our efforts to develop a malaria vaccine.'
Meanwhile, another European Union malaria drug research project WISDOM has announced it has analysed 140 million potential docking arrangements between drug compounds and target malaria proteins using a grid of 5,000 computers over 10 weeks in 27 countries, generating 2,000 gigabytes of useful data.